Evaluation of malignancy risk in scleroderma by antibody profile. Lertphanichkul C, Smith GP. Br J Dermatol 2021;184:369-371.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lertphanichkul C, Smith GP. Evaluation of malignancy risk in scleroderma by antibody profile. Br J Dermatol 2021;184:369-371.
PMID: 32920853